Drug intelligence / Profile preview

ART-300

Development stage: Preclinical
Lead developer: Arum Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

ART-300 is a preclinical-stage small molecule antiviral agent being developed by Arum Therapeutics. It is specifically designed to prevent or treat exacerbations of asthma and chronic obstructive pulmonary disease (COPD) triggered by viral infections. The program is currently in the hit-to-lead and lead optimization phases. While the specific molecular target has not been publicly disclosed, the drug's mechanism is intended to mitigate the inflammatory and symptomatic spikes in respiratory patients caused by common viral pathogens.

Other names: ART-300ART300ART 300

Targets

PI4KB (Phosphatidylinositol 4-kinase beta)

Beyond the preview

Go deeper on ART-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART-300.

Explore the full profile